Towards Understanding the Use of Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Understanding-the-Use-of-Hydroxychloroquine-PLS-Image
Scientific Study Title:
Hydroxychloroquine in systemic lupus
Start Date:
End Date:
Glen Hazlewood-Website Headshot-400x400
Glen Hazlewood
Research Scientist, Rheumatology, MD, PhD, FRCPC
Susan Bartlett- Website Headshot-400x400
Susan Bartlett
Research Scientist, Medicine, PhD, M-ARP
Ann Clarke-Website Headshot-400x400
Ann Clarke
Research Scientist, Immunology, MD, MSc, FRCPC
CNDTCuObPcKpCY6crUEYRn4B3svXwMJQ9-QmU5eFW1E
Paul Fortin
Senior Scientist, Rheumatology, MD, MPH, FRCPC
iAPIwJt8fXo1AW_OpaKC-A44VD9vdC8pB_T175A3qyo
Linda Li
Senior Scientist, Implementation Science, BSc(PT), MSc, PhD, FCAHS

Ready to Participate?

Life-changing arthritis research is only possible with your help!

Why do this research?

Reason For Research

Systemic lupus erythematosus (SLE) is a disease in which the immune system is overactive, causing inflammation in various organs including joints and skin. There are areas where better approaches in SLE could improve outcomes. One example relates to hydroxychloroquine (HCQ), a drug which can reduce the risk of serious disease flares. However, the main side effect of long-term use of HCQ is eye damage. At present, we cannot accurately predict which patients with SLE are most likely to have a flare of their SLE symptoms once we lower the dose of HCQ. Also, it is not clear what causes the risk of eye damage. Our study will fill these knowledge gaps and add information about patient preferences for HCQ use.

Methodology

Execution of Research

Our research will link and analyze data on 3,700 SLE patients across Canada to:

  1. evaluate factors associated with a poor outcome among patients with SLE who lower but do not stop HCQ (poor outcome being a significant increase in disease activity, hospitalization for SLE symptoms or need for increased therapy).
  2. determine factors associated with a poor outcome among patients with SLE who stop HCQ (poor outcome being a significant increase in disease activity, hospitalization for SLE symptoms or need for increased therapy).
  3. evaluate the relationship between HCQ use and occurrence of eye damage (retinal toxicity) in patients with SLE, and if it is associated with population characteristics and clinical characteristics.
  4. assess the preferences of patients with SLE for HCQ therapy and if preferences are associated with population characteristics and clinical factors. We will use interviews and a ‘discrete choice’ survey design.

Related Research